Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Tegafur: Patents, clinical trial progress, indications

Tegafur is an investigational drug.

There have been 119 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Taiwan University Hospital.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Tegafur
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2
S-1 for 9 Months Versus 1 Year for Gastric Cancer Staged II(SMAC)Fudan UniversityPhase 2
Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisZhejiang Cancer HospitalPhase 2

See all Tegafur clinical trials

Clinical Trial Summary for Tegafur

Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur

See all Tegafur clinical trials

US Patents for Tegafur

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur   Start Trial Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA)   Start Trial
Tegafur   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Tegafur   Start Trial Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same Protalix Ltd. (Carmiel, IL)   Start Trial
Tegafur   Start Trial Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Tegafur   Start Trial Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL)   Start Trial
Tegafur   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur Australia 2014232383 2033-03-15   Start Trial
Tegafur Australia 2019202731 2033-03-15   Start Trial
Tegafur Brazil 112015023267 2033-03-15   Start Trial
Tegafur Canada 2906931 2033-03-15   Start Trial
Tegafur China 105142635 2033-03-15   Start Trial
Tegafur Eurasian Patent Organization 201591607 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.